Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 59.5% in February

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 104,500 shares, a growth of 59.5% from the January 31st total of 65,500 shares. Based on an average daily volume of 114,000 shares, the short-interest ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Trading Up 2.6 %

NASDAQ:ENTX traded up $0.05 during trading hours on Tuesday, reaching $1.98. 50,246 shares of the company were exchanged, compared to its average volume of 151,718. The stock’s 50-day moving average is $2.30 and its 200-day moving average is $2.00. Entera Bio has a twelve month low of $1.30 and a twelve month high of $3.35. The firm has a market cap of $70.85 million, a PE ratio of -7.62 and a beta of 1.62.

Institutional Trading of Entera Bio

Several large investors have recently made changes to their positions in ENTX. Knoll Capital Management LLC boosted its position in Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after acquiring an additional 2,000,000 shares during the last quarter. Northern Trust Corp purchased a new position in Entera Bio in the 4th quarter worth approximately $450,000. Perigon Wealth Management LLC purchased a new position in Entera Bio in the 4th quarter worth approximately $325,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Entera Bio during the 3rd quarter worth approximately $90,000. Finally, Parkman Healthcare Partners LLC grew its position in shares of Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.